Clearside reduces sublicense fees to high single digit; maintenance fees set $250K-$500K for 2023-2028

Clearside Biomedical, Inc.

Sublicense percentage reduced from low double digits to high single digits for fees received from sublicensees.
Maintenance fees: $250K for 2023-2025, $350K for 2026, $400K for 2027, $500K for 2028.
2023 maintenance fee of $250K due within 5 days of amendment execution (Jan 31, 2024).
Reduced sublicense fee excludes R&D reimbursements, IP value transfers, and stock payments.
Royalty rate on product sales remains unchanged at low single digit.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Clearside Biomedical, Inc. amended License Agreement with Emory University valued at reduction of Sublicense Percentage from a low double digit to a high single digit; revised annual li (effective 2024-01-31).

Action: amendment
Agreement: license
Counterparty: Emory University
Value: reduction of Sublicense Percentage from a low double digit to a high single digit; revised annual li
Effective: 2024-01-31

Exact text from the filing

On January 31, 2024 (the “ Amendment Execution Date ”), Clearside Biomedical, Inc. (the “ Company ”), Emory University (“ Emory ”) and Georgia Tech Research Corporation (together with Emory, the “ Licensor ”), entered into an amendment (the “ Amendment ”) to the Company’s License Agreement with Licensor dated July 4, 2012 (as amended, the “ License Agreement ”), pursuant to which the Company received a worldwide exclusive license to specified patents relating to methods and devices for drug delivery using a microinjector.

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-009767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.